No. You cannot get a prescription for retatrutide right now. It is not FDA approved. It is not TGA approved in Australia. It is not approved anywhere in the world as of 2025.
But the data behind it is serious, and people are asking about it constantly. So here is everything you need to know about where it stands, what it does, and what your actual options are today.
What Phase Are Retatrutide Clinical Trials In?
Retatrutide is currently in Phase 3 clinical trials. Eli Lilly, the company developing it, moved it into Phase 3 after Phase 2 results came back in 2023 showing weight loss numbers that surprised a lot of researchers.
In the Phase 2 trial published in the New England Journal of Medicine, participants lost up to 24.2% of their body weight over 48 weeks. That is more than semaglutide (Ozempic, Wegovy) and more than tirzepatide (Mounjaro, Zepbound) showed at the same stage of development.
Phase 3 means larger groups, longer timeframes, and more safety data. These trials are running now. Eli Lilly has not announced a specific approval submission date, but based on typical trial timelines, an FDA submission could come in 2025 or 2026, with potential approval following 6 to 12 months after that.
In my experience tracking how these drug timelines play out, Phase 3 completion to approval usually takes 18 to 36 months from when Phase 3 starts. Retatrutide Phase 3 started in late 2023. That puts a realistic approval window somewhere between late 2025 and 2027, depending on how the data looks and how fast the FDA moves.
Who Is Developing Retatrutide?
Eli Lilly is developing retatrutide. They also make tirzepatide, which is sold as Mounjaro for type 2 diabetes and Zepbound for weight loss. Lilly has been the most aggressive pharmaceutical company in the GLP-1 space over the last three years.
Retatrutide is a triple agonist. It targets three receptors at once, GLP-1, GIP, and glucagon. Semaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits three. That glucagon receptor activation is what makes it different, and it is likely why the weight loss numbers are higher.
The glucagon component increases energy expenditure. Your body burns more calories at rest. Combined with the appetite suppression from GLP-1 and GIP activation, the effect compounds. What I found interesting in the Phase 2 data was that the weight loss did not plateau as early as it does with semaglutide. People kept losing weight further into the trial.
How Does Retatrutide Differ From Other Weight Loss Medications?
Here is a direct comparison based on the best available trial data.
- Semaglutide (Wegovy) produces around 15% body weight loss over 68 weeks in the STEP 1 trial. It is a GLP-1 receptor agonist only.
- Tirzepatide (Zepbound) produces around 20.9% body weight loss over 72 weeks in the SURMOUNT-1 trial. It hits GLP-1 and GIP receptors.
- Retatrutide produced up to 24.2% body weight loss over 48 weeks in Phase 2. It hits GLP-1, GIP, and glucagon receptors.
The 48-week timeframe for retatrutide is shorter than the semaglutide and tirzepatide trials, which makes the comparison even more striking. More weight lost, faster, in a shorter window.
Side effects in Phase 2 were similar to other GLP-1 drugs. Nausea, vomiting, and diarrhea were the most common, mostly during dose escalation. No new safety signals appeared that were not already seen with semaglutide or tirzepatide. Phase 3 will give a clearer picture with a much larger population.
One thing worth noting is that retatrutide also showed meaningful reductions in liver fat and improvements in metabolic markers beyond just weight. For people with non-alcoholic fatty liver disease or metabolic syndrome, that is relevant data.
Is Retatrutide Available by Prescription Right Now?
No. There is no legal pathway to get a retatrutide prescription anywhere in the world right now. It does not exist as an approved drug. No doctor can prescribe it through a standard pharmacy.
The only people currently receiving retatrutide are enrolled in clinical trials. If you want to explore trial participation, ClinicalTrials.gov lists active Phase 3 studies. Eligibility criteria typically include a BMI of 30 or above, or 27 or above with a weight-related health condition. You would need to find a trial site near you and go through a screening process.
Trial participation is not a shortcut. It involves regular monitoring, possible placebo assignment, and strict protocols. But it is the only legitimate way to access retatrutide before approval.
Can You Get Retatrutide Through a Compounding Pharmacy?
This is where people get into trouble. The short answer is no, and here is why.
Compounding pharmacies in the US and Australia have been legally producing semaglutide and tirzepatide during shortage periods because those drugs are FDA and TGA approved. Compounders can make versions of approved drugs under specific conditions.
Retatrutide is not approved. It is not on any shortage list. There is no legal basis for a compounding pharmacy to produce it. Any pharmacy or online clinic claiming to sell compounded retatrutide is operating outside the law, and the product they are selling is not retatrutide. It is an unverified research chemical with no quality control, no dosing standards, and no safety data in a real-world setting.
In my experience, when a drug gets this much attention before approval, grey market versions appear fast. I have already seen websites selling what they call retatrutide peptides. These are research chemicals. They are not pharmaceutical grade. You do not know what is in them, what the actual dose is, or what the long-term effects are. The risk is not worth it.
How Can I Access Retatrutide Before It Is Approved?
Realistically, your options are limited to two paths.
- Clinical trial enrollment. Search ClinicalTrials.gov for active retatrutide Phase 3 trials. Contact the trial sites directly. This is the only way to access the actual drug with medical supervision and safety monitoring.
- Wait for approval. Based on current timelines, approval in the US could come as early as late 2025 or more likely 2026 to 2027. Australian TGA approval typically follows 12 to 24 months after FDA approval, though Lilly may pursue simultaneous submissions.
There is no third option that is both legal and safe. Anyone telling you otherwise is selling you something.
What Should You Do Right Now If You Want to Lose Weight?
This is the practical question. Retatrutide is not available. But effective, approved options are.
Semaglutide and tirzepatide are both approved and available with a prescription. Tirzepatide in particular produces weight loss results that were considered impossible five years ago. A 20% reduction in body weight is a meaningful clinical outcome. For most people, that is enough to address the health risks they are trying to manage.
What I found when looking at the data across all three drugs is that the difference between tirzepatide and retatrutide, while real, is not massive for most people. Going from 20% to 24% body weight loss matters at the population level. For an individual, the bigger variable is adherence, diet quality, and whether you are building habits that sustain results after you stop the medication.
Can you get a prescription for retatrutide today? No. But you can get a prescription for drugs that work well right now, and you can build the foundation that makes any medication more effective.
Working with a coach who understands how GLP-1 medications interact with training and nutrition makes a real difference. The medication suppresses appetite. It does not build muscle, improve your relationship with food, or teach you how to eat when you come off it. That is where structured support matters.
FAQ
Is retatrutide the same as semaglutide?
No. Semaglutide is a GLP-1 receptor agonist. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. They work through overlapping but distinct mechanisms, and retatrutide has shown higher weight loss in trials so far.
When will retatrutide be approved?
No confirmed date exists. Based on Phase 3 timelines, a realistic window for FDA approval is 2026 to 2027. TGA approval in Australia would likely follow 12 to 24 months after that.
Can a doctor prescribe retatrutide off-label?
No. Off-label prescribing applies to approved drugs used for unapproved indications. Retatrutide is not approved for any indication, so off-label prescribing is not possible.
Is retatrutide safe?
Phase 2 data showed a side effect profile similar to other GLP-1 drugs, mainly nausea and GI symptoms during dose escalation. Phase 3 will provide more comprehensive safety data. Long-term safety in a broad population is not yet established.
What is the dose of retatrutide used in trials?
Phase 2 tested doses up to 12mg weekly. The highest dose group showed the greatest weight loss. Phase 3 is testing specific doses to determine the optimal balance of efficacy and tolerability.
Will retatrutide be covered by insurance?
Unknown. Coverage will depend on approval status, indication, and individual insurance plans. Current GLP-1 drugs have inconsistent coverage, so this will likely be a challenge at launch as well.
